ArticleJournal of biomedical science2020
Structural basis of polyethylene glycol recognition by antibody.
Article in Journal of biomedical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Effective Reduction of Anti-PEG Antibody Recognition via PEG Copolymers with Ethyl Glycidyl Ether and Isopropyl Glycidyl Ether.Biomacromolecules · 2026Article
- A Non-Antigenic Randomized Polyethylene Glycol/Poly(2-Phenyl-2-Oxazine)-Based Drug Delivery Platform.Macromolecular rapid communications · 2026Article
- Anti-PEG Immunogenicity of mRNA-LNP Vaccines in Humans: Evidence for Population-Level Changes in the Anti-PEG Antibody Repertoire.Pharmaceutics · 2026Article
- Structural basis of B-to-Z DNA transition mediated by an anti-Z-DNA antibody.Nucleic acids research · 2026Article
- AFM-Based Single-Molecule Force Spectroscopy of PEG-Anti-PEG Antibody Interactions.ACS applied bio materials · 2026Article
- The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer.Cancer medicine · 2025Review
- Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines.Nanomedicine (London, England) · 2025Review
- Isomerization of Poly(ethylene glycol): A Strategy for the Evasion of Anti-PEG Antibody Recognition.Journal of the American Chemical Society · 2025Article
- Recent Advances in Vitamin E TPGS-Based Organic Nanocarriers for Enhancing the Oral Bioavailability of Active Compounds: A Systematic Review.Pharmaceutics · 2025Review
- PEG-mCherry interactions beyond classical macromolecular crowding.Protein science : a publication of the Protein Society · 2025Article
- Antigenicity Extension: A Novel Concept Explained by the Immunogenicity of PEG.ACS bio & med chem Au · 2025Article
- Context-dependent effect of polyethylene glycol on the structure and dynamics of hirudin.Biophysical journal · 2025Article
- A multiplex microarray lateral flow immunoassay device for simultaneous determination of five mycotoxins in rice.NPJ science of food · 2024Article
- Molecular Crowding: The History and Development of a Scientific Paradigm.Chemical reviews · 2024Review
- Supramolecular Synthons in Protein-Ligand Frameworks.Crystal growth & design · 2024Article
- Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Cinnamyl-Modified Polyglycidol/Poly(ε-Caprolactone) Block Copolymer Nanocarriers for Enhanced Encapsulation and Prolonged Release of Cannabidiol.Pharmaceutics · 2023Article
- Crystal structure of a three-tetrad, parallel, KActa crystallographica. Section F, Structural biology communications · 2023Article
- Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.ACS nano · 2023Article
- Hidden hydrophobicity impacts polymer immunogenicity.Chemical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPolyethylene glycol (PEG) is widely used in industry and medicine. Anti-PEG antibodies have been developed for characterizing PEGylated drugs and other applications. However, the underlying mechanism for specific PEG binding has not been elucidated.
methodsThe Fab of two cognate anti-PEG antibodies 3.3 and 2B5 were each crystallized in complex with PEG, and their structures were determined by X-ray diffraction. The PEG-Fab interactions in these two crystals were analyzed and compared with those in a PEG-containing crystal of an unrelated anti-hemagglutinin 32D6-Fab. The PEG-binding stoichiometry was examined by using analytical ultracentrifuge (AUC).
resultsA common PEG-binding mode to 3.3 and 2B5 is seen with an S-shaped core PEG fragment bound to two dyad-related Fab molecules. A nearby satellite binding site may accommodate parts of a longer PEG molecule. The core PEG fragment mainly interacts with the heavy-chain residues D31, W33, L102, Y103 and Y104, making extensive contacts with the aromatic side chains. At the center of each half-circle of the S-shaped PEG, a water molecule makes alternating hydrogen bonds to the ether oxygen atoms, in a similar configuration to that of a crown ether-bound lysine. Each satellite fragment is clamped between two arginine residues, R52 from the heavy chain and R29 from the light chain, and also interacts with several aromatic side chains. In contrast, the non-specifically bound PEG fragments in the 32D6-Fab crystal are located in the elbow region or at lattice contacts. The AUC data suggest that 3.3-Fab exists as a monomer in PEG-free solution but forms a dimer in the presence of PEG-550-MME, which is about the size of the S-shaped core PEG fragment.
conclusionsThe differing amino acids in 3.3 and 2B5 are not involved in PEG binding but engaged in dimer formation. In particular, the light-chain residue K53 of 2B5-Fab makes significant contacts with the other Fab in a dimer, whereas the corresponding N53 of 3.3-Fab does not. This difference in the protein-protein interaction between two Fab molecules in a dimer may explain the temperature dependence of 2B5 in PEG binding, as well as its inhibition by crown ether.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.